The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Human Ovarian Cancer and Cisplatin Resistance: Possible Role of Inhibitor of Apoptosis Proteins1
Abstract
The inhibitor of apoptosis proteins (IAPs) constitutes a family of highly conserved apoptosis suppressor proteins that were originally identified in baculoviruses. Although IAP homologs have recently been demonstrated to suppress apoptosis in mammalian cells, their expression and role in human ovarian epithelial cancer and chemotherapy resistance are unknown. In the present study we used cisplatin-sensitive and -resistant human ovarian surface epithelial (hOSE) cancer cell lines and adenoviral antisense and sense complementary DNA expression to examine the role of IAP in the regulation of apoptosis in human ovarian cancer cells and chemoresistance. Antisense down-regulation of X-linked inhibitor of apoptosis protein (Xiap), but not human inhibitor of apoptosis protein-2 (Hiap-2), induced apoptosis in cisplatin-sensitive and, to a lesser extent, in -resistant cells. Cisplatin consistently decreased Xiap content and induced apoptosis in the cisplatin-sensitive, but not cisplatin-resistant, cells. Hiap-2 expression was either unaffected or inhibited to a lesser extent. The inhibition of IAP protein expression and induction of apoptosis by cisplatin was time and concentration dependent. Infection of cisplatin-sensitive cells with adenoviral sense Xiap complementary DNA resulted in overexpression of Xiap and markedly attenuated the ability of cisplatin to induce apoptosis. Immunohistochemical localization of the IAPs in hOSE tumors demonstrated the presence of Xiap and Hiap-2, with their levels being highest in proliferative, but not apoptotic, epithelial cells. These studies indicate that Xiap is an important element in the control of ovarian tumor growth and may be a point of regulation for cisplatin in the induction of apoptosis. These results suggest that the ability of cisplatin to down-regulate Xiap content may be an important determinant of chemosensitivity in hOSE cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Cited by
Molecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564
The inhibitors of apoptosis (IAPs) as cancer targets
Hunter, A. M., LaCasse, E. C., & Korneluk, R. G. (2007) · Apoptosis · doi:10.1007/s10495-007-0087-3 · Cited by 565
Self-citationSafaei, R., Larson, B. J., Cheng, T. C., Gibson, M. A., Otani, S., Naerdemann, W., & Howell, S. B. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0102 · Cited by 564
IAP-targeted therapies for cancer
LaCasse, E. C., Mahoney, D. J., Cheung, H. H., Plenchette, S., Baird, S., & Korneluk, R. G. (2008) · Oncogene · doi:10.1038/onc.2008.302 · Cited by 524
Self-citationDeath receptors in chemotherapy and cancer
Debatin, K.-M., & Krammer, P. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207558 · Cited by 505
Apoptosis pathways in cancer and cancer therapy
Debatin, K.-M. (2004) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0474-8 · Cited by 476
The inhibitors of apoptosis: there is more to life than Bcl2
Liston, P., Fong, W. G., & Korneluk, R. G. (2003) · Oncogene · doi:10.1038/sj.onc.1207101 · Cited by 440
Self-citationCisplatin resistance: Preclinical findings and clinical implications
Köberle, B., Tomicic, M. T., Usanova, S., & Kaina, B. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.07.004 · Cited by 361
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies
Chen, X., Duan, N., Zhang, C., & Zhang, W. (2016) · Journal of Cancer · doi:10.7150/jca.13332 · Cited by 347
Notarbartolo, M., Poma, P., Perri, D., Dusonchet, L., Cervello, M., & D'Alessandro, N. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.10.051 · Cited by 317
Chemosensitization of tumors by resveratrol
Gupta, S. C., Kannappan, R., Reuter, S., Kim, J. H., & Aggarwal, B. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05852.x · Cited by 305
Self-citationRole of mitochondrial membrane permeabilization in apoptosis and cancer
Henry-Mowatt, J., Dive, C., Martinou, J.-C., & James, D. (2004) · Oncogene · doi:10.1038/sj.onc.1207534 · Cited by 274
The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer
NACHMIAS, B., ASHHAB, Y., & BENYEHUDA, D. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.04.002 · Cited by 266
Alterations in the apoptotic machinery and their potential role in anticancer drug resistance
Kaufmann, S. H., & Vaux, D. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206945 · Cited by 265
Small molecule modulators of protein-protein interactions: selected case studies
Aeluri, M., Chamakuri, S., Dasari, B., Guduru, S. K. R., Jimmidi, R., Jogula, S., & Arya, P. (2014) · Chemical Reviews · doi:10.1021/cr4004049 · Cited by 79
Therapeutics Targeting the Core Apoptotic Machinery
Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A. (2021) · Cancers · doi:10.3390/cancers13112618 · Cited by 26
Metadata
- Authors
- Li, J., Feng, Q., Kim, J.-M., Schneiderman, D., Liston, P., Li, M., Vanderhyden, B., Faught, W., Fung, M. F. K., Senterman, M., Korneluk, R. G., & Tsang, B. K.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2001-01
- Volume
- 142
- Issue
- 1
- Pages
- 370-380
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2104979289
- Cited by
- 185
- References
- 1
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.